Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors

about

Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors

Item

http://www.wikidata.org/entity/Q58719429

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2018

@uk

name

Comparison of reversal activit ...... eparin and oral FXa inhibitors

@en

Comparison of reversal activit ...... eparin and oral FXa inhibitors

@nl

type

Item

label

Comparison of reversal activit ...... eparin and oral FXa inhibitors

@en

Comparison of reversal activit ...... eparin and oral FXa inhibitors

@nl

prefLabel

Comparison of reversal activit ...... eparin and oral FXa inhibitors

@en

Comparison of reversal activit ...... eparin and oral FXa inhibitors

@nl

P1476

Comparison of reversal activit ...... eparin and oral FXa inhibitors

@en

P2093

A Louise Creagh

http://www.w3.org/2001/XMLSchema#string

Anjali Pandey

http://www.w3.org/2001/XMLSchema#string

Charles Haynes

http://www.w3.org/2001/XMLSchema#string

Genmin Lu

http://www.w3.org/2001/XMLSchema#string

Jayachandran N Kizhakkedathu

http://www.w3.org/2001/XMLSchema#string

Manu T Kalathottukaren

http://www.w3.org/2001/XMLSchema#string

Mark J Karbarz

http://www.w3.org/2001/XMLSchema#string

Pamela B Conley

http://www.w3.org/2001/XMLSchema#string

Srinivas Abbina

http://www.w3.org/2001/XMLSchema#string

P2860

NIH Image to ImageJ: 25 years of image analysis

Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab

Idarucizumab for Dabigatran Reversal

Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents.

Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Development and validation of a high throughput whole blood thrombolysis plate assay.

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa

Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.

P304

2104-2114

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOODADVANCES.2016003616

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-08-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30135185

http://www.w3.org/2001/XMLSchema#string

P932

6113616

http://www.w3.org/2001/XMLSchema#string